Objective: Development and validation of a simple and standardized self-reporting questionnaire for acute uncomplicated cystitis (AUC) assessing typical and differential symptoms, quality of life and possible changes after therapy in female patients with AUC. Materials and Methods: Literature research, development and evaluation of the Acute Cystitis Symptom Score (ACSS), an 18-item self-reporting questionnaire including (a) six questions about ‘typical' symptoms of AUC, (b) four questions regarding differential diagnoses, (c) three questions on quality of life and (d) five questions on additional conditions which may affect therapy. The ACSS was evaluated in 286 women (mean age 32.3 ± 12.3 years) in the Russian and Uzbek language. Measurements of reliability, validity, predictive ability and responsiveness were performed. Results: Cronbach's alpha for the ACSS was 0.89, split-half reliability was 0.92 and correlation between halves was 0.85. Mann-Whitney test revealed significant difference scores of the ‘typical' domain between patients and controls (10.75 vs. 2.02, p < 0.001). The optimal threshold score was 6 points, with a 94% sensitivity and 90% specificity to predict AUC. The symptom score decreased significantly when comparing before and after therapy (10.7 vs. 2.1, p < 0.001). Conclusion: The new validated ACSS is accurate enough and can be recommended for clinical studies and practice for initial diagnosis and monitoring treatment of AUC. Evaluation in other languages is in progress. © 2014 S. Karger AG, Basel

1.
Foxman B, Brown P: Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 2003;17:227-241.
2.
Ronald AR, Nicolle LE, Stamm E, Krieger J, Warren J, Schaeffer A, Naber KG, Hooton TM, Johnson J, Chambers S, Andriole V: Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents 2001;17:343-348.
3.
Schappert SM, Rechtsteiner EA: Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13 2011;169:1-38.
4.
Colgan R, Keating K, Dougouih M: Survey of symptom burden in women with uncomplicated urinary tract infections. Clinical Drug Investig 2004;24:55-60.
5.
Ernst EJ, Ernst ME, Hoehns JD, Bergus GR: Women's quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment. Health Qual Life Outcomes 2005;3:45.
6.
Foxman B, Gillespie B, Koopman J, Zhang L, Palin K, Tallman P, Marsh JV, Spear S, Sobel JD, Marty MJ, Marrs CF: Risk factors for second urinary tract infection among college women. Am J Epidemiol 2000;151:1194-1205.
7.
Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE: Risk factors for recurrent urinary tract infection in young women. J Infect Dis 2000;182:1177-1182.
8.
Zincir H, Kaya Erten Z, Ozkan F, Sevig U, Baser M, Elmali F: Prevalence of urinary tract infections and its risk factors in elementary school students. Urol Int 2012;88:194-197.
9.
Berg AO: Variations among family physicians' management strategies for lower urinary tract infection in women: a report from the Washington Family Physicians Collaborative Research Network. J Am Board Fam Pract 1991;4:327-330.
10.
Wigton RS, Longenecker JC, Bryan TJ, Parenti C, Flach SD, Tape TG: Variation by specialty in the treatment of urinary tract infection in women. J Gen Intern Med 1999;14:491-494.
11.
Yamamichi F, Shigemura K, Matsumoto M, Nakano Y, Tanaka K, Arakawa S, Fujisawa M: Relationship between urinary tract infection categorization and pathogens' antimicrobial susceptibilities. Urol Int 2012;88:198-208.
12.
Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S: Does this woman have an acute uncomplicated urinary tract infection? JAMA 2002;287:2701-2710.
13.
Bent S, Saint S: The optimal use of diagnostic testing in women with acute uncomplicated cystitis. Am J Med 2002;113(suppl 1A):20S-28S.
14.
Schauberger CW, Merkitch KW, Prell AM: Acute cystitis in women: experience with a telephone-based algorithm. WMJ 2007;106:326-329.
15.
Clayson D, Wild D, Doll H, Keating K, Gondek K: Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire. BJU Int 2005;96:350-359.
16.
Wild DJ, Clayson DJ, Keating K, Gondek K: Validation of a patient-administered questionnaire to measure the activity impairment experienced by women with uncomplicated urinary tract infection: the Activity Impairment Assessment (AIA). Health Qual Life Outcomes 2005;3:42.
17.
Barry HC, Ebell MH, Hickner J: Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract 1997;44:49-60.
18.
Akilov FA, Naber KG, Rakhmonov OM, Alidjanov JF, Abdufattaev UA: Development and validation of self-administered questionnaire to assess severity of acute cystitis symptoms and their influence to quality of life: Urinary Symptoms and Quality of Life Assessment Tool (USQOLAT). Collected Articles of ‘Current Problems of Theoretical and Practical Medicine'. Almaty, Kazakhstan, 2011, pp 225-229.
19.
Bleidorn J, Gagyor I, Kochen MM, Wegscheider K, Hummers-Pradier E: Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? Results of a randomized controlled pilot trial. BMC Med 2010;8:30.
20.
Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ: The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis 2004;36:296-301.
21.
Malterud K, Baerheim A: Peeing barbed wire. Symptom experiences in women with lower urinary tract infection. Scand J Prim Health Care 1999;17:49-53.
22.
Savaris RF, Teixeira LM, Torres TG: Bladder tenderness as a physical sign for diagnosing cystitis in women. Int J Gynaecol Obstet 2006;93:256-257.
23.
Novik AA, Ionova TI, Kind P: Conception of Life Quality Research in Medicine. Saint Petersburg, Elby, 1999.
24.
Spilker B: Quality of Life and Pharmacoeconomics in Clinical Trials, ed 2. Philadelphia, Lippincott-Raven, 1996.
25.
Staquet MJ, Hays RD, Fayers PM: Quality of Life Assessment in Clinical Trials: Methods and Practice. Oxford, NY, Oxford University Press, 1998.
26.
Staquet M, Berzon R, Osoba D, Machin D: Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 1996;5:496-502.
27.
Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549-1557, discussion 1564.
28.
Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun EA, Pontari MA, Alexander RB, Farrar JT, O'Leary MP: The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999;162:369-375.
29.
Baerheim A, Digranes A, Jureen R, Malterud K: Generalized symptoms in adult women with acute uncomplicated lower urinary tract infection: an observational study. MedGenMed 2003;5:1.
30.
Ellis AK, Verma S: Quality of life in women with urinary tract infections: is benign disease a misnomer? J Am Board Fam Pract 2000;13:392-397.
31.
Little P, Merriman R, Turner S, Rumsby K, Warner G, Lowes JA, Smith H, Hawke C, Leydon G, Mullee M, Moore MV: Presentation, pattern, and natural course of severe symptoms, and role of antibiotics and antibiotic resistance among patients presenting with suspected uncomplicated urinary tract infection in primary care: observational study. BMJ 2010;340:b5633.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.